Skip to main content
Publications
Braitmaier M, Kollhorst B, Heinig M, Langner I, Czwikla J, Heinze F, Buschmann L, Minnerup H, Garcia-Albeniz X , Hense HW, Karch A, Zeeb H, Haug U, Didelez V. Effectiveness of mammography screening on breast cancer mortality - a study protocol for emulation of target trials using German health claims data . Clin Epidemiol. 2022 Nov 2;14:1293-303. doi: 10.2147/CLEP.S376107
Arana A , Pottegard A, Kuiper J, Booth H, Reutfors J, Calingaert B , Lund LC, Crellin E, Schmitt-Egenolf M, Kaye J, Gembert K, Rothman K , Kieler H, Dedman D, Houben E, Gutierrez L , Hallas J, Perez-Gutthann S . Long-term risk of skin cancer and lymphoma in users of topical tacrolimus and pimecrolimus: final results from the extension of the cohort study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE) . Clin Epidemiol. 2021 Dec 29;2021(13):1141-53. doi: 10.2147/CLEP.S331287
Anthony MS , Armstrong MA, Getahun D, Scholes D, Gatz J, Schulze-Rath R, Postlethwaite D, Merchant M, Alabaster AL, Chillemi G, Raine-Bennett T, Xie F, Chiu VY, Im TM, Takhar HS, Fassett M, Grafton J, Cronkite D, Ichikawa L, Reed SD, Hui SL, Ritchey ME, Saltus CW , Andrews EB, Rothman KJ , Asiimwe A, Lynen R, Schoendorf J. Identification and validation of uterine perforation, intrauterine device expulsion, and breastfeeding in four health care systems with electronic health records . Clin Epidemiol. 2019 Jul 23;2019(11):635-43. doi: 10.2147/CLEP.S201044
Castellsague J, Kuiper JG, Pottegard A, Anveden Berglind I, Dedman D, Gutierrez L , Calingaert B , van Herk-Sukel MP, Hallas J, Sundstrom A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ , Perez-Gutthann S . A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation – JOELLE study) . Clin Epidemiol. 2018 Mar 13;2018(10):299-310. doi: 10.2147/CLEP.S146442
Mazurek M, Huisman MV, Rothman KJ , Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Lu S, Lip GYH, GLORIA-AF Investigators. Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF phase II registry . Thromb Haemost. 2017 Dec;117(12):2376-88. doi: 10.1160/TH17-08-0555
Yosipovitch G, Reaney M, Mastey V, Eckert L, Nelson L , Clark M , Abbe A, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis . Poster presented at the 2017 American Academy of Dermatology Annual Meeting; March 4, 2017. Orlando, FL. [abstract] J Am Acad Dermatol. 2017 Jun; 76(6 Suppl 1):AB278. doi: 10.1016/j.jaad.2017.04.1082
Strober B, Gottlieb AB, Sherif B , Mollon P, Gilloteau I, McLeod L , Fox T, Mordin M , Gnanasakthy A , Papavassilis C, Lebwohl MG. Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept . J Am Acad Dermatol. 2017 Apr;76(4):655-61. doi: 10.1016/j.jaad.2016.11.043
Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B , Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB273. Previously presented at the 24th European Academy of Dermatology and Venereology Congress. doi: 10.1016/j.jaad.2016.02.1054
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M , Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1049
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B , Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1050
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B , McLeod L , Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1051
Blauvelt A, Korman N, Mollon P, Zhao Y, Milutinovic M, You R, Sherif B , Williams N, Fox T, Augustin M. Secukinumab treatment provides faster and more effective relief from patient-reported quality-of-life impact than ustekinumab in subjects with moderate to severe plaque psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5[S1]):AB273. Previously presented at the 24th European Academy of Dermatology and Venereology Congress. doi: 10.1016/j.jaad.2016.02.1053
Kimball AB, Rothman KJ , Kricorian G, Pariser D, Yamauchi PS, Menter A, Teller CF, Aras G, Accortt NA, Hooper M, Rice KC, Gelfand JM. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results . J Am Acad Dermatol. 2015 Jan;72(1):115-22. doi: 10.1016/j.jaad.2014.08.050
Mannila MN, Silveira A, Hawe E , Eriksson P, Aillaud MF, Juhan-Vague I, Yudkin J, Margaglione M, di Minno G, Mussoni L, Tremoli E, Humphries S, Hamsten A, Hifmech Study Group. Plasma fibrinogen concentration predicts the risk of myocardial infarction differently in various parts of Europe: effects of beta-fibrinogen genotype and environmental factors. The HIFMECH Study . Thromb Haemost. 2004 Dec;92(6):1240-9.
Konstantoulas C, Hawe E , Saut N, Yudkin JS, di Minno G, Margaglione M, Hamsten A, Humphries SE, Juhan-Vague I, Ireland H, Hifmech Study Group. Common variants in the thrombomodulin gene as a risk for myocardial infarction in the north of Europe (HIFMECH Study) . Thromb Haemost. 2004 Mar;91(3):628-30.
Kelberman D, Hawe E , Luong LA, Mohamed-Ali V, Lundman P, Tornvall P, Aillaud MF, Juhan-Vague I, Yudkin JS, Margaglione M, di Minno G, Tremoli E, Humphries SE, Hifmech Study Group. HIFMECH study group. Effect of Interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe. The HIFMECH Study . Thromb Haemost. 2004;92(5):1122-8.